Observations placeholder
Tracleer and Bosentan
Identifier
015757
Type of Spiritual Experience
Background
A description of the experience
Bosentan is a dual endothelin receptor antagonist used in the treatment of pulmonary artery hypertension (PAH). It is licensed in the United States, the European Union and other countries by Actelion Pharmaceuticals for the management of PAH under the trade name Tracleer.
Bosentan is a competitive antagonist of endothelin-1 at the endothelin-A (ET-A) and endothelin-B (ET-B) receptors. Under normal conditions, endothelin-1 binding of ET-A or ET-B receptors causes constriction of the pulmonary blood vessels. By blocking this interaction, bosentan decreases pulmonary vascular resistance. Bosentan has a slightly higher affinity for ET-A than ET-B.
On Dec, 23, 2016 41,375 people reported to have side effects when taking Tracleer.
Among them, 8,524 people (20.6%) have Death
Time on Tracleer when people have Death :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Death | 11.77% | 19.34% | 12.87% | 17.41% | 27.25% | 11.10% | 0.25% |
On Jan, 04, 2017 41,375 people reported to have side effects when taking Tracleer.
Among them, 64 people (0.15%) have Hallucination
Time on Tracleer when people have Hallucination :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Hallucination | 52.38% | 19.05% | 14.29% | 14.29% | 0.00% | 0.00% | 0.00% |
Gender of people who have Hallucination when taking Tracleer :
Female | Male | |
Hallucination | 69.57% | 30.43% |
Age of people who have Hallucination when taking Tracleer :
0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
Hallucination | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 27.78% | 5.56% | 66.67% |
The source of the experience
eHealthmeConcepts, symbols and science items
Concepts
Symbols
Science Items
Activities and commonsteps
Activities
Overloads
Endothelial dysfunctionHeart failure and coronary heart disease
Hypertension
Vasodilators